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ABSTRACT: (Antifungal activity of actinobacteria against fungus isolates of clinical importance). The escalating use of 
antifungal agents and long-term treatment approaches has led to an increased prevalence of fungus species that are resistant 
to the most common antifungal drugs. Actinobacteria produce a wide variety of bioactive secondary metabolites. This study 
investigated actinomycete isolates with the potential to produce bioactive compounds against dermatophyte fungus species and 
Candida spp. of clinical importance. Antifungal activity of actinomycetes was assessed using the double-layer agar technique. 
Active isolates were cultivated in starch casein broth (SCB) at 30 ºC for 8 days. Aliquots were retrieved at 24-h intervals and 
centrifuged to obtain extracts. Extract activity was assessed using the well-diffusion method. No dermatophyte fungus isolate 
was inhibited in the double-layer assay, although isolates 1S, R18(6) and 6(2) were active against all Candida spp. used in the 
assay. The well-diffusion method revealed that isolate R18(6) inhibited the six Candida spp. in a 72-h growth period in SCB 
broth, showing good potential to yield a compound with antifungal activity.
Key words: bioactive compounds, Candida spp., dermatophyte fungi.
RESUMO: (Atividade antifúngica de actinobactérias contra fungos isolados de importância clínica).O uso crescente de anti-
fúngicos e os tratamentos prolongados vêm aumentando a incidência de fungos resistentes às drogas antifúngicas comumente 
utilizadas. As actinobactérias são conhecidas por produzirem uma grande variedade de metabólitos secundários bioativos e este 
trabalho teve como objetivo selecionar isolados de actinomicetos com potencial para produção de compostos bioativos contra 
fungos dermatófitos e espécies de Candida de importância clínica. A atividade antifúngica dos actinomicetos foi avaliada pela 
técnica da dupla camada. Os isolados que apresentaram atividade foram cultivados em caldo amido caseína (AC) à temperatura 
de 30 ºC por oito dias e foram retiradas e centrifugadas alíquotas a cada 24h, para obtenção do extrato. A atividade dos extratos 
foi avaliada através da técnica de difusão em poço. Nenhum dos isolados de fungos dermatófitos foi inibido no ensaio de dupla 
camada e os isolados 1S, R18(6) e 6(2) mostraram atividade frente todas as espécies de Candida testadas. No ensaio de difusão 
em poço com os extratos, o isolado R18(6) inibiu as seis espécies de Candida em 72h de crescimento em caldo AC e mostrou 
grande potencial para obtenção de composto com atividade antifúngica.
Palavras-chave: compostos biativos, Candida spp., fungos dermatófitos.
INTRODUCTION
The occurrence of fungal infections in humans has 
increased significantly in the past 30 years (Lass-Flörl 
2009). Among the various antimicrobial agents currently 
marketed, antifungal substances comprise a compara-
tively small but nevertheless important group of medici-
nal drugs with a key role in the treatment of a variety of 
mycoses (Thakur et al. 2007). Compared to antibacterial 
agents, the number of antifungal compounds approved 
for use in humans is quite limited, a circumstance ex-
plained by the high toxicity of these substances to the 
hosts. However, it comes as no surprise that the use of 
antifungal drugs has led to the selection of resistant fungi 
populations. As described by Rex et al. (1995), resistant 
strains find their way to hosts in three colonization and 
infection scenarios: (i) exposure to an initially susceptible 
strain that subsequently mutates and becomes resistant; 
(ii) exposure to a number of strains of which one is re-
sistant and eventually is the only one to thrive, resisting 
the presence of antifungal drugs in the host organism; 
and (iii) exposure to an inherently resistant strain. The 
escalating use of antifungal agents in long-term treatment 
strategies has raised the prevalence of fungus strains that 
are resistant to the most commonly prescribed antifungal 
agents (Selmecki et al. 2009). Additionally, the larger 
number of opportunistic infections in immunosuppressed 
patients, together with the growing resistance exhibited 
by these fungus species, poses a considerable challenge 
to the pharmaceutical industry in the search for safe and 
efficient antifungal drugs (Dhanasekaran et al. 2008).
Secondary microbial metabolites represent a major 
source of compounds with remarkable chemical struc-
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tures and potent biological activity (Arasu et al. 2009). 
Bacteria belonging to the actinomyctes group exhibit 
several physiological and metabolic attributes, such as 
the production of extracellular enzymes and of a variety 
of secondary metabolites (Ventura et al. 2007). Their 
apparently unlimited ability to produce bioactive com-
pounds makes actinomycetes especially useful in the 
development of new medicinal drugs. Thousands of these 
compounds have been isolated and characterized, and 
several are used in the treatment of diseases in humans 
as well as in veterinary medicine and agriculture (Arasu 
et al. 2008). These microorganisms are responsible for 
the production of more than half of the commercially 
available bioactive compounds, including antibiotics, 
immunosuppressant drugs, antitumor agents and enzymes 
(Qin et al. 2009). Considering the importance of new 
active compounds against fungi, the aim of this study 
was to obtain actinomycete strains with the potential 
to produce bioactive compounds against dermatophyte 
fungi and Candida spp. with clinical importance.
MATERIALS AND METHODS
Samples 
Twenty-five actinomycete isolates were used in the 
antagonism assay against six Candida spp. (Candida 
albicans – ATCC10231, Candida glabrata – CG01, Can-
dida krusei – CK03, Candida parapsilosis – CP06, Can-
dida tropicalis – CT08 and Candida dubliniensis - 24P), 
and 40 were used in the assay to test for activity against 
five dermatophyte fungi (Epidermophyton floccosum – 
EF31, Microsporum gypseum -MGY45, Microsporum 
canis – MCW3, Trichophyton metagrophytes – TMW1 
and Trichophyton rubrum – TRW2). All actinomycetes 
used were provided by the Laboratory of Environmental 
Microbiology. Department of Microbiology, Immunol-
ogy and Parasitology, Federal University of Rio Grande 
do Sul (UFRGS), Brazil. All fungal isolates used were 
isolated were obtained from the culture collections of the 
Laboratory of Applied Mycological Research, UFRGS.
Fungal susceptibility profiling
The disk-diffusion method was used to assess the sus-
ceptibility of Candida isolates to the antifungal agents 
fluconazole and nystatin (BIO-RAD, Brazil). The assay 
was conducted in accordance with the standards defined 
by CSLI M44-A (2004), with modifications. Mueller-
Hilton agar with 2% glycose were used, in which a 0.5 
McFarland scale cell suspension was inoculated. The 
antifungal were placed on the surface of the agar disk and 
incubated at 30 ºC for 24 h and 48 h. After incubation, 
all disks were analyzed.
Evaluation of antifungal activity
Antifungal activity was assessed using the double-
layer method. Actinomycete isolates were inoculated us-
ing the spot-inoculation method onto plates with mineral 
salts-starch-casein-agar (SCA) medium (10.0 g starch, 
0.3 g casein, 2.0 g K2HPO4, 2.0 g NaCl, 2.0 g KNO3, 
0.05 g MgSO4 .7H2O, 0.01 g Fe2(SO4)3.6H2O, 15.0 g 
agar) and incubated at 30 ºC for 10 days. Dermatophyte 
fungus and yeast isolates were inoculated in Sabouraud 
dextrose agar and incubated at 30 ºC for seven days and 
48 h, respectively. All assays were conducted so that the 
incubation periods of fungi and actinomycete isolates 
would end concurrently. 
Fungi grown in Petri plates were used to prepare the 
spore suspensions. For that, 3 mL of 0.8% sterile saline 
was added to plates containing the dermatophyte fungi, 
and the spores were removed using a Drigalski loop. 
The mixture was transferred to sterile glass test tubes 
and the final spore concentration was adjusted to 5 x 104 
spores/mL. Inoculums of yeast strains were standard-
ized using the 0.5 McFarland scale (1.5 x 108 cells/mL). 
Of these suspensions, a 1 mL aliquot was retrieved and 
homogenized in 9 mL melted Sabouraud dextrose agar. 
This mixture was poured on the plates containing cul-
tured actinomycetes. Plates were incubated at 30 ºC for 
seven days and 48 h, for filamentous fungi and yeasts, 
respectively. Then, the presence of inhibition halos was 
examined. The antibiosis index (AI) was calculated as 
the mean inhibition halo divided by the mean colony 
diameter (Rosato et al. 1981).
Submerged cultures
Actinomycetes with antifungal potential were selected 
to produce an active compound in submerged culture. Ex-
tracts were prepared in two steps. First, the pre-inoculum 
was prepared, in which the antagonist isolate was inocu-
lated in 50 mL starch casein broth (SCB) and incubated 
for 48 h at 30 ºC with constant shaking at 100 rpm. After, 
a 5 mL aliquot was transferred to conical 250 mL vials 
containing 50 mL of the SCB medium. Cultures were 
grown for eight days under the same conditions as the 
pre-inoculum. Aliquots from the culture were retrieved 
every 24 h to assess antimicrobial activity; the aliquots 
were centrifuged for 10 min at 13,000 rpm to separate 
the cells and obtain a cell-free extract.
Antifungal activity of the crude extract
Antifungal activity of the crude extract was assessed 
using the well-diffusion method. By means of a sterile 
cork borer, wells were punctured in plates containing 
Sabouraud dextrose agar previously seeded with one of 
the Candida isolates. One hundred microliters (100 mL) 
of supernatant of each isolate was added in each well. 
The plates were incubated at 8-10 °C for 16 h for the 
diffusion of the bioactive compound, and then incubated 
at 30 ºC for 48 h. After the incubation period, inhibition 
halos were measured and the antibiosis index calculated.
RESULTS
Of the 25 actinomycete isolates used in the double-
layer assay with the six Candida spp., 11 (44%) inhibited 
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Actinomycetes C. dubliniensis C. albicans C. parapsilosis C. krusei C. glabrata C. tropicalis
1s 0.33(0)* 0.31(0.07) 0.81(0.07) 1.83(0.35) 0.42(0) 1.00(0.56)
R18(6) 1.28(0.14) 0.58(0.42) 1.50(0.35) 1.27(0.07) 0.93(0.07) 1.15(0.21)
6(4) 0 0.44(0.28) 0.11(0) 0.33(0.14) 0.36(0.21) 0.37(0.14)
R(11)6 0.78(0.35) 0.75(0.49) 0.23(0.14) 0.36(0.35) 0 1.87(0.35)
24(3) 0 0.33(0) 0 0.10(0.07) 0.55(0.07) 0.15(0.07)
2(4) 0 0.27(0) 0 0 0.33(0) 0.13(0.07)
6(2) 0.90(0.07) 0.80(0) 1.00(0.14) 0.50(0.07) 1.25(0.35) 0.53(0.28)
8(4) 0 0.33(0) 0 0 0 0
27(3) 0 0.29(0) 0 0.16(0.14) 0 0.22(0.07)
5(3) 0 0.30(0) 0 0 0.50(0.14) 0.07(0)
iso5(5) 1.30(0.07) 0.27(0.14) 0 0.50(0.14) 1.00(0.14) 0
*. Standard deviation.
Table 1. Antibiosis index values obtained in the double-layer assay for actinomycete isolates against six different Candida spp. isolates.
growth of at least one of the yeasts used (Table 1) and 
no antagonism was recorded with dermatophyte fungi. 
Therefore, the search for active compounds against der-
matophyte fungi was discontinued for the time being.
Of the 11 actinomycete isolates showing antifungal 
activity against yeast species, one inhibited only one 
(16.6%) Candida species, three inhibited the growth of 
three (50%) species, two showed activity against four 
(66.6%), and two others inhibited five (83.3%) species 
(Table 1). Three of the actinomycete isolates (R18(S), 1S 
and 6(2)) inhibited the growth of all six (100%) Candida 
spp. used (Table 1).
Actinomycete isolates R18(6), 1S and 6(2), which 
exhibited antifungal activity against the six Candida spp. 
used in the double-layer assay, were grown in submerged 
culture. The antifungal activity of the metabolic liquid 
was assessed according to the well-diffusion method. 
Isolates 1S and 6(2) did not inhibit the growth of yeasts 
when grown in SCB. Isolate R18(6) exhibited inhibition 
halos against all six Candida spp. (Fig. 1). As early as 
24 h after the beginning of growth and until 96 h, the 
compound produced by isolate R18(6) inhibited the 
growth of C. dubliniensis, C. parapsilosis, C. krusei and 
C. tropicalis. Inhibition of C. albicans and C. glabrata 
was observed after 72 h of growth.
The fungal susceptibility profiling assay was carried 
out to evaluate the susceptibility of Candida spp. isolates 
to the antifungal agents fluconazole and nystatin, using 
the agar disk-diffusion assay. The results showed that five 
of the six Candida isolates were resistant to fluconazole. 
In contrast, five of the isolates exhibited intermediate 
susceptibility to nystatin (Table 2).
DISCUSSION
Fluconazole is a triazole antifungal agent that is well 
tolerated and safe, and its clinical action against most 
strains of Candida spp. is considered good. However, the 
increased use of this drug has led to the selection of re-
sistant strains (Santos Jr. et al. 2005). Additionally, some 
species, such as C. glabrata and C. krusei, are naturally 
less susceptible to fluconazole (Dovigo et al. 2009). In 
the present study, only the isolate of C. parapsilosis was 
susceptible to fluconazole. Wingter et al. (2007) observed 
a 10% resistance to fluconazole and 2% resistance to ny-
statin in Candida spp. isolated from HIV+ patients. Loss 
of susceptibility to currently marketed drugs prescribed to 
treat infections caused by Candida spp. has been reported 
in various studies (Colombo et al. 2006, Mujica et al. 
2004, Favalessa et al. 2010), and the observations in the 
present study concord with these findings.
Research on the biological properties of actinomycetes 
has shown that these bacteria are potential candidates for 
the production of antifungal compounds. Bachiega et al. 
(2005) reported that 20.3% (13/64) of the actinomycete 
isolates studied were active against C. albicans. More 
recently, Gandotra et al. (2012) observed that 33.3 (3/9) 
of Streptomyces spp. analyzed showed some degree of 
activity against Candida spp. isolates. Additionally, 
several studies have proved that actinomycetes exhibit 
antifungal properties, especially against C. albicans, 
with values ranging between 4.9% (101/2041) (Hong et 
al. 2009) and 12.5% (1/8) (Susithra et al. 2009). In the 
present study, the double-layer assay showed that 44% of 
the isolates (11/25) had an antifungal effect on the yeast 
strains tested. Compared to results reported elsewhere, 
this proportion is comparatively high, and shows good 
promise for the production of bioactive compounds that 
inhibit clinically important Candida spp.
None of the actinomycete isolates assayed exhib-
ited activity against dermatophyte fungi. The search 
Samples Fluconazole Nystatina
C. dubliniensis R I
C. albicans R I
C. glabrata R S
C. krusei R I
C. parapsilosis S I
C. tropicalis R I
 
Table 2. Results obtained with the fungal susceptibility assay for 
Candida isolates. 
 Abbreviations: R, resistant; I, intermediary; S, susceptible.
442 Spadari et al.
R. bras. Bioci., Porto Alegre, v. 11, n. 4, p. 439-443, out./dez. 2013
Figure 1. Antibiosis index (AI) obtained for isolate R18(6) in SCA broth at 30 ºC against six different Candida spp. isolates (PI, pre-inoculum).
for antifungal substances active against dermatophyte 
fungi has faced considerable obstacles. Augustine et al. 
(2005) tested 218 actinomycete isolates, and observed 
that only one (0.45%) exhibited activity against fungi of 
this group. Similarly, of the 100 isolates tested by Lak-
shmipathy and Kannabiran (2009), only 3% were active 
against dermatophyte fungus species. In turn, Deepa et 
al. (2011) isolated 30 actinomycetes from soils, of which 
five (16%) exhibited activity against Microsporum spp. 
However, these authors observed that, by sorting these 
bioactive compounds by thin-layer chromatography, the 
Rf values obtained were similar to those exhibited by 
commercially available antifungal compounds, which 
may indicate that these compounds are responsible for 
the antifungal action of these isolates.
Of the extracts produced in submerged culture, isolates 
1S and 6(2) did not retain their antifungal activity as 
detected in the double-layer assay. Research has shown 
that the production of antibiotic compounds is more ef-
ficient in solid culture media, compared with submerged 
media, in which activity may decrease or even cease 
completely. Thakur et al. (2007) reported that, of 65 iso-
lates that showed antibacterial activity in solid medium, 
15 failed to do so in liquid medium. Similar results were 
described by other authors (Salamoni et al. 2010, Anibou 
et al. 2008). The production of antibiotic compounds in 
liquid media is generally low, and the detection of bio-
active compounds requires high concentrations of them 
(Oliveira et al. 2010).
Isolate R18(6), when grown in SCA at 30 ºC, retained 
its antifungal activity observed in the double-layer assay, 
inhibiting the six Candida spp. used when inhibition was 
assessed for the 72-h growth period. However, analysis 
of the data obtained here (Figure 1) suggests that isolate 
R18(6) produces more than one bioactive compound, 
since it was only after 72 h of growth that C. albicans 
and C. glabrata were also inhibited by it, in addition to 
the other Candida spp., which may be due to the pro-
duction of a second active compound. Previous studies 
have found more than one molecule with antimicrobial 
activity in bacterial isolates of the actinomycete group 
(Badji 2006, Boudjella et al. 2006, Smaoui et al. 2012).
The study conducted by Oliveira et al. (2010), using 
the same isolate R18(6), showed that it has potential in 
the biocontrol of phytopathogens (filamentous fungi and 
bacteria) that affect tomato plantations. In the present 
study, only R18(6) inhibited all Candida spp. used, when 
grown in submerged medium. Therefore, this isolate can 
be considered an efficient target for use in the production 
of antifungal compounds against Candida spp. with clini-
cal importance, and further studies should be conducted 
to isolate and characterize its bioactive molecule.
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